MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
convertible notes
$56,500K
Proceeds from issuance of
common stock upon...
$1,803K
Net cash provided by
financing activities
$55,761K
Canceled cashflow
$2,542K
Net increase in
cash, cash...
$34,584K
Canceled cashflow
$21,177K
Payment of deferred
offering costs
$2,218K
Payment of third-party
debt issuance costs
$324K
Loss on
remeasurement of convertible...
$8,594K
Stock-based compensation
$1,467K
Accounts payable
$1,339K
Depreciation and
amortization expense
$1,167K
Non-cash operating lease
costs
$461K
Convertible note issuance
costs included in net...
$361K
Unrealized foreign
exchange loss (gain)
-$165K
Change in fair value of
warrant liabilities
$84K
Amortization of debt issuance
costs
$67K
Net cash used in
operating activities
-$20,347K
Net cash (used in)
provided by investing...
-$778K
Effect of exchange rate
changes on cash and cash...
-$52K
Canceled cashflow
$13,705K
Net loss
-$21,325K
Purchases of property and
equipment
$600K
Capitalized software
development costs
$178K
Accounts receivable
$6,854K
Prepaid expenses and
other current assets
$1,960K
Inventory
$1,265K
Accrued expenses and
other liabilities
-$1,234K
Operating lease
liabilities
-$1,087K
Other noncurrent
assets
$327K
Back
Back
Cash Flow
Alamar Biosciences, Inc. (ALMR)
Alamar Biosciences, Inc. (ALMR)
source: myfinsight.com